Skip to main content

Table 1 Patient characteristics by study groups

From: Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand

Parameters

cisplatin (N = 137)

carboplatin (N = 76)

P-value

Age (years)

51.6 (21–67)

53.8 (35–70)

0.051

Maximal diameter of primary tumor(cm)

4.5 (2–8)

4.3(2–9)

0.4

Stage

  

0.09

IIB

91(66.4 %)

43(56.6 %)

IIIA

0

2(2.6 %)

IIIB

44(32.1 %)

31(40.8 %)

IVA

2(1.5 %)

0

Pelvic Lymph nodes

  

0.63

No

72(52.6 %)

45(59.2 %)

Yes

14(10.2 %)

6(7.9 %)

Unknown

51(37.2 %)

25(32.9 %)

Histology

  

0.4

SCCA

114(83.2 %)

66(86.8 %)

ACA

21(15.3 %)

9(11.8 %)

Others

2(1.5 %)

1(1.3 %)

Histologic grade

  

0.66

1

18(14.8 %)

9(13.4 %)

2

78(63.9 %)

47(70.1 %)

3

26(21.3 %)

11(16.4 %)

Cycles

  

0.02

Up to 4 cycles

38 (27.7 %)

10(13.2 %)

5 to 6 cycles

99(72.3 %)

66(86.8 %)

Total treatment time (days)

56.8 (34–114)

56(43–173)

0.39

Median follow-up time (months)

39.8(6–69)

40.6(6–69)

0.76

  1. Note: SCCA squamous cell carcinoma, ACA adenocarcinoma